Glucose-1-phosphokinase

After 48 h, marked increase in blood glucose, depressed plasma insulin level, marked depletion of liver glycogen, significant increase in plasma creatinine phosphokinase and glutamic oxaloacetic transaminase activity (Giri etal. 1979)... 

Creatine phosphokinase activity has been reported to be minimally inhibited by hemolysis. Hemoglobin concentrations of 1.25 g/100 ml inhibit 5% and 2.5 g/100 ml, 12% (N5). However, in methods utilizing adenosine diphosphate in the reaction mixture, hemolysates containing 100 mg of hemoglobin per 100 ml may have apparent activities of 5-100 units/liter. The activity is presumably related to adenylate kinase in the erythrocyte (S33). In methods utilizing adenosine diphosphate in a coupled enzyme reaction with hexokinase and glucose-6-phosphatase, the inhibitory effect can be eliminated by adding sufficient adenosine mono-... 

Rather than being reincorporated into inositol phospholipids, DAG can be broken down to release some arachidonate which is the precursor of prostaglandin E which, in turn, can react with plasma membrane receptors linked to adenyl cyclase and cAMP production. IL-3 does not activate phospholipase C but does promote phosphorylation of the glucose transporter by phosphokinase C (Dexter and Spooner, 1987). 

Therapeutic doses of morphine can alter the blood activities of amylase, lipase, lactate dehydrogenase, creatine phosphokinase, and leucine aminopeptidase, BSP retention, and urine glucose concentration (Benedict s) (57-59). 

Disturbances in lipid metabolism also may occur, resulting in transitory increase of blood values for cholesterol and triglycerides. Liver function and serum lipids should initially be monitored, typically at baseline and at weeks 4 and 8. Serious adverse effects of isotretinoin therapy include increased creatine phosphokinase and blood glucose, as well as photosensitivity, pseudotumor cerebri, excess granulation tissue, hepatomegaly with abnormal liver function tests, bone abnormalities, arthralgias, muscle stiffness, and headaches. ... 

B. Other useful laboratory studies include electrolytes, glucose, BUN, creatinine, liver function tests, creatine phosphokinase, and arterial blood gases. 

The first equation is a reflection of the energy needed to maintain the brain function (ATPase) when the production of ATP by oxidative phosphorylation is compromised the second (creatine phosphokinase) and third (myokinase) reactions are secondary pathways attempting to maintain the ATP levels. In addition, ATP can be produced by anaerobic glycolysis and this explains the relative depletion of the glucose-related metabolites and a tenfold increase in lactate with a resulting acidosis (data not shown.). 

Substrate-Limited Reactions. As individual steps in a sequence approach their equilibria, the rate of reaction decreases. The fermentation of glucose catalyzed by yeast extracts illustrates the effect of product accumulation. Normally ATP is considered a desirable product, and, as it plays a catalytic role in glycolysis, is not considered in estimating the progress of the reaction. In most crude extracts active phosphatases hydrolyze ATP and prevent its accumulation. Glycolyzing yeast extracts, however, were found to be stimulated by the addition of apyrase, which formed ADP from ATP. Thus glycolysis was shown to be limited at the phosphokinase steps by limiting concentrations of ADP, the phosphate acceptor, or by excessive concentrations of ATP that favored the back reactions. 

The longitudinal, postmarketing, observational PATRO children study (N = 1837, mean age = 9.33 years, 56.9% male) found that adverse events associated with Omnitrope with an incidence rate >0.001 (based on 2851.16 patient years) were headache, hypothyroidism, arthralgia, pain in extremity, injection-site haematoma, decreased glucose tolerance, asthenia, injection-site pain, increased blood creatine, phosphokinase and myalgia [36 -]. There were no confirmed cases of diabetes (type 1 or 2) or malignancy related to treatment and no anti-hGH antibodies have been found in a subset of 30 patients. 

Scheme 17. 1) phosphoglucomutase 2) UDP-glucose pyrophosphorylase 3) UDP-galactose-4 epimerase 4) P(l-4)galacfosyl transferase 5) phosphokinase. 

---